Danburstotug

达布苏塔单抗

Report date: 2023/05/05 17:09:50

Base Information

Drug NameDanburstotug
Drug Alias NameIMC-001STI-3031STI-A1015
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionImmunomodulatorsProgrammed death-ligand 1 blockers
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisBiliary Tract Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth KoreaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSorrento Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesImmuneoncia Therapeutics IncYuhan Corp
Inactive CompaniesSorrento Therapeutics Inc
Active IndicationsLymphoma, Extranodal NK-T-CellLymphoma
Inactive IndicationsSolid tumoursNeoplasm MetastasisBiliary Tract Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A